List of Studies ( Metabolite:1-DeoxyCer 18:0;O/16:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST002343 | AN003827 | The impact of myriocin and dietary serine restriction on paw skin sphingolipid diversity | Skin | Mouse | Salk Institute for Biological Studies | LC-MS | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Brain | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Liver | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST001063 | AN001740 | Lipidomics analysis for aged mice organs | Muscle | Mouse | Takeda Pharmaceutical Company Limited | LC-MS | |
| ST000917 | AN001501 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000916 | AN001495 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
| ST000915 | AN001489 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | GC-MS/LC-MS |
